New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:44 EDTRHHBYGenentech announced that ADACTA study results will be presented oN November 11
Genentech, a member of the Roche Group announced that results from the ADACTA study will be presented on November 11 during an oral presentation at the 2012 American College of Rheumatology, ACR, Annual Scientific Meeting in Washington, D.C. Results from the study showed ACTEMRA (tocilizumab) improved signs and symptoms (DAS28 score reduction) of rheumatoid arthritis (RA) significantly more than adalimumab when used alone as a single-agent therapy (without other disease-modifying antirheumatic drugs, DMARDs, including methotrexate). RA patients are often treated with a combination of medicines that typically include a biologic medicine, such as ACTEMRA or adalimumab, plus methotrexate. However, about one in three patients on a biologic treatment such as ACTEMRA or adalimumab receive it as a single-agent therapy, largely due to intolerance to methotrexate.
News For RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 22, 2015
15:14 EDTRHHBYExelixis confirms Phase 3 data on Cotellic with Zelboraf for melanoma
Subscribe for More Information
15:09 EDTRHHBYGenentech reports data on Cotellic with Zelboraf for treatment of melanoma
Genentech, a member of the Roche Group, announced data from the pivotal coBRIM study, showing that Cotellic, or cobimetinib, in combination with Zelboraf, or vemurafenib, helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live "significantly longer" than with Zelboraf alone, according to the company. Cotellic plus Zelboraf reduced the risk of death by 30% compared to Zelboraf alone and helped people live a median of nearly two years, with 74.5% of BRAF V600 patients alive at one year and 48.3% alive at two years. Ongoing study monitoring did not identify any new safety signals. The company noted that an approval decision on Cotellic from the European Commission is expected before year end.
November 18, 2015
08:28 EDTRHHBYLeerink to hold a bus tour
Subscribe for More Information
08:11 EDTRHHBYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
November 17, 2015
07:34 EDTRHHBYOphthotech to hold a conference call
Subscribe for More Information
06:08 EDTRHHBYRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information
November 13, 2015
10:18 EDTRHHBYRoche receives FDA approval for cobas EGFR mutation test
Subscribe for More Information
09:34 EDTRHHBYFDA approves Roche's cobas EGFR Mutation Test
Subscribe for More Information
November 12, 2015
11:50 EDTRHHBYRoche to restructure manufacturing network for small molecules
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use